Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias
Expert Rev Hematol. 2023 Jul 5. doi: 10.1080/17474086.2023.2233701. Online ahead of print.ABSTRACTINTRODUCTION: Acute Myeloid Leukemia (AML) is an aggressive disease which has traditionally been treated with intensive chemotherapy. Survival in patients with high risk cytogenetic and molecular subsets has been poor with this approach due to suboptimal responses seen with intensive chemotherapy and due to many patients with higher risk disease being older and unable to tolerate intensive therapies. In recent years, several targeted therapies have been under investigation for patients with high-risk AML subsets.AREAS COVERED:...
Source: Expert Review of Hematology - July 5, 2023 Category: Hematology Authors: Kieran D Sahasrabudhe Mary Albrethsen Alice S Mims Source Type: research
Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients
CONCLUSION: Hydroxyurea reduces the expression of phosphatidylserine on erythrocytes, contributing to the beneficial effects of this therapy. We suggest that the use of such a biological marker in conjunction with HbF levels may provide valuable insights into the biology and consequences of early RBC apoptosis.PMID:37394969 | DOI:10.1080/17474086.2023.2231152 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 3, 2023 Category: Hematology Authors: Neha Kargutkar Anita Nadkarni Source Type: research
Impact of genotype on clinical course in sickle cell disease and the utility of neutrophil-lymphocyte ratio: a ten-year single-institution experience
CONCLUSION: This study supports the utility of NLR as an accessible adjunctive clinical tool in SCD prognostication.PMID:37395002 | DOI:10.1080/17474086.2023.2231637 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 3, 2023 Category: Hematology Authors: Akash Mathavan Akshay Mathavan Mohit Mathavan Urszula Krekora Aaron J Winer Ellery Altshuler Russell Wnek Keegan Hones Arushi Thaper Richard Artola Logan Pucci Patrick Haley Del Carter William Snead Denise Manfrini Daniel Leach Jess D DeLaune Molly W Mand Source Type: research
Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients
CONCLUSION: Hydroxyurea reduces the expression of phosphatidylserine on erythrocytes, contributing to the beneficial effects of this therapy. We suggest that the use of such a biological marker in conjunction with HbF levels may provide valuable insights into the biology and consequences of early RBC apoptosis.PMID:37394969 | DOI:10.1080/17474086.2023.2231152 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 3, 2023 Category: Hematology Authors: Neha Kargutkar Anita Nadkarni Source Type: research
Impact of genotype on clinical course in sickle cell disease and the utility of neutrophil-lymphocyte ratio: a ten-year single-institution experience
CONCLUSION: This study supports the utility of NLR as an accessible adjunctive clinical tool in SCD prognostication.PMID:37395002 | DOI:10.1080/17474086.2023.2231637 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - July 3, 2023 Category: Hematology Authors: Akash Mathavan Akshay Mathavan Mohit Mathavan Urszula Krekora Aaron J Winer Ellery Altshuler Russell Wnek Keegan Hones Arushi Thaper Richard Artola Logan Pucci Patrick Haley Del Carter William Snead Denise Manfrini Daniel Leach Jess D DeLaune Molly W Mand Source Type: research
Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint
Expert Rev Hematol. 2023 Jul 4:1-8. doi: 10.1080/17474086.2023.2232547. Online ahead of print.ABSTRACTINTRODUCTION: It is important to know the current status of hemophilic arthropathy diagnoses, treatments, complications, and outcomes in developed countries.AREAS COVERED: A bibliographic search in PubMed for articles published from 1 January 2019 through 12 June 2023 was performed.EXPERT OPINION: In developed countries with specialized hemophilia treatment centers, primary hematological prophylaxis (started before the age of 2 years and after no more than one joint bleed) has almost completely eliminated the joint-related...
Source: Expert Review of Hematology - July 1, 2023 Category: Hematology Authors: E Carlos Rodriguez-Merchan Source Type: research
Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint
Expert Rev Hematol. 2023 Jul 1. doi: 10.1080/17474086.2023.2232547. Online ahead of print.ABSTRACTINTRODUCTION: It is important to know the current status of hemophilic arthropathy diagnoses, treatment, complications, and outcomes in developed countries.AREAS COVERED: A bibliographic search in PubMed for articles published from 1 January 2019 through 12 June 2023 was performed.EXPERT OPINION: In developed countries with specialized hemophilia treatment centers, primary hematological prophylaxis (started before the age of 2 years and after no more than one joint bleed) has almost completely eliminated the joint-related prob...
Source: Expert Review of Hematology - July 1, 2023 Category: Hematology Authors: E Carlos Rodriguez-Merchan Source Type: research
Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment
Expert Rev Hematol. 2023 Jun 20:1-9. doi: 10.1080/17474086.2023.2226859. Online ahead of print.ABSTRACTINTRODUCTION: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for roughly 5% of all Hodgkin lymphoma (HL) cases. In contrast to classical HL, the malignant cells in NLPHL are positive for CD20 but lack CD30. The disease usually has an indolent clinical course resulting in high long-term survival rates.AREAS COVERED: In this review, treatment options for NLPHL are summarized and factors that may help to individualize treatment are discussed.EXPERT OPINION: Stage IA NLPHL without...
Source: Expert Review of Hematology - June 20, 2023 Category: Hematology Authors: Dennis A Eichenauer Sylvia Hartmann Source Type: research
